Fonte: Marine Drugs. Unidade: ICB
Assuntos: FARMACOLOGIA, CÉLULAS CULTIVADAS DE TUMOR, APOPTOSE, PRODUTOS NATURAIS, MELANOMA, NEOPLASIAS CUTÂNEAS, MOLÉCULA, INFECÇÕES BACTERIANAS GRAM-POSITIVAS
ABNT
HIRATA, Amanda Soares et al. Preclinical development of seriniquinones as selective dermcidin modulators for the treatment of melanoma. Marine Drugs, v. 20, n. 5, p. 1-13, 2022Tradução . . Disponível em: https://doi.org/10.3390/md20050301. Acesso em: 03 nov. 2024.APA
Hirata, A. S., Clair, J. J. L., Jimenez, P. C., Costa-Lotufo, L. V., & Fenical, W. (2022). Preclinical development of seriniquinones as selective dermcidin modulators for the treatment of melanoma. Marine Drugs, 20( 5), 1-13. doi:10.3390/md20050301NLM
Hirata AS, Clair JJL, Jimenez PC, Costa-Lotufo LV, Fenical W. Preclinical development of seriniquinones as selective dermcidin modulators for the treatment of melanoma [Internet]. Marine Drugs. 2022 ; 20( 5): 1-13.[citado 2024 nov. 03 ] Available from: https://doi.org/10.3390/md20050301Vancouver
Hirata AS, Clair JJL, Jimenez PC, Costa-Lotufo LV, Fenical W. Preclinical development of seriniquinones as selective dermcidin modulators for the treatment of melanoma [Internet]. Marine Drugs. 2022 ; 20( 5): 1-13.[citado 2024 nov. 03 ] Available from: https://doi.org/10.3390/md20050301